Relationship between plasma anti-β2-glycoprotein Ⅰ and cardiovascular disease in systemic lupus erythematosus
10.3760/cma.j.issn.1007-7480.2012.06.013
- VernacularTitle:血清抗β2糖蛋白Ⅰ抗体与系统性红斑狼疮患者心血管病变的关系
- Author:
Juan MENG
;
Yi ZHENG
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus,systemic;
Cardiovascular diseases;
Anti-β2-glycopmtein Ⅰ
- From:
Chinese Journal of Rheumatology
2012;16(6):414-417
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between plasma anti-β2-glycoprotein I (anti-β2-GP I )and cardiovascular disease (CVD) in systemic lupus erythematosus (SLE).Methods Eighty-onepatients with SLE [the mean age was (45±18) years old,among whom 73 were female and 8 were male] and20 controls [the mean age was (43±17) years old,among whom 14 were female,and 6 were male] wereenrolled.Plasma anti-β2-GP I was measured by ELLSA.The relationship between plasma anti-β2-GP I level and CVD in SLE patients was investigated with Logistic regression model.T-test,x2 test,Spearman's correlations and Logistic regression analysis were used for statistical analysis.Results Mean plasma anti-β2-GP I increased significantly in SLE group compared to control group [ (29± 19) vs (14±8) U/ml,t=2.035,P＜0.05].The plasma levels of anti-β2-GP I were higher in SLE patients with CVD than those without [(41±25)vs (18±12) U/ml,t=2.038,P＜0.05].Plasma anti-β2-GP I level was positively correlated with triglyceride (r=0.337,P＜0.05) and renal lesions (r=0.489,P＜0.01 ).Plasma anti-B2-GP [ level was negatively correlated with high density lipoproteins (r=-0.385,P＜0.05 ) and complement (r=-0.497,P＜0.05 ) level.Logistic regression analysis showed that plasma anti-β2-GP I (β=0.675,95％CI0.5070.816,P＜0.05) was an independent risk factor for CVD in SLE patients.Conclusion The level of plasma anti-β2-GP I in SLE patients with CVD is high,and it may play a role in the pathogenesis and progression of CVD in SLE patients.
